Medical cannabis, or medical marijuana, can refer to the use of cannabis and its cannabinoids to treat disease or improve symptoms; however, there is no single agreed-upon definition.[38][39] The rigorous scientific study of cannabis as a medicine has been hampered by production restrictions and other federal regulations.[40] There is limited evidence suggesting cannabis can be used to reduce nausea and vomiting during chemotherapy, to improve appetite in people with HIV/AIDS, and to treat chronic pain and muscle spasms.[41][42][43] Its use for other medical applications is insufficient for conclusions about safety or efficacy.
Recreational cannabis use centers around one chemical: the psychoactive cannabinoid tetrahydrocannabinol (THC). Consuming this chemical induces euphoric and stimulating sensations commonly referred to as a “high.” For most marijuana users, these sensations are pleasurable and enjoyable. For some, however, THC can induce feelings of anxiety and paranoia, especially in large doses.
Research suggests that CBD may exert some of its pharmacological action through its inhibition of fatty acid amide hydrolase (FAAH), which may in turn increase the levels of endocannabinoids, such as anandamide, produced by the body.[8] It has also been speculated that some of the metabolites of CBD have pharmacological effects that contribute to the biological activity of CBD.[43]

The basic commercial options for growing hemp in North America is as a fiber plant, an oilseed crop, or for dual harvest for both seeds and fiber. Judged on experience in Canada to date, the industry is inclined to specialize on either fiber or grain, but not both. Hemp in our opinion is particularly suited to be developed as an oilseed crop in North America. The first and foremost breeding goal is to decrease the price of hempseed by creating more productive cultivars. While the breeding of hemp fiber cultivars has proceeded to the point that only slight improvements can be expected in productivity in the future, the genetic potential of hemp as an oilseed has scarcely been addressed. From the point of view of world markets, concentrating on oilseed hemp makes sense, because Europe has shown only limited interest to date in developing oilseed hemp, whereas a tradition of concentrating on profitable oilseed products is already well established in the US and Canada. Further, China’s supremacy in the production of high-quality hemp textiles at low prices will be very difficult to match, while domestic production of oilseeds can be carried out using technology that is already available. The present productivity of oilseed hemp—about 1 t/ha under good conditions, and occasional reports of 1.5 to 2 t/ha, is not yet sufficient for the crop to become competitive with North America’s major oilseeds. We suggest that an average productivity of 2 t/ha will be necessary to transform hempseed into a major oilseed, and that this breeding goal is achievable. At present, losses of 30% of the seed yields are not uncommon, so that improvements in harvesting technology should also contribute to higher yields. Hemp food products cannot escape their niche market status until the price of hempseed rivals that of other oilseeds, particularly rapeseed, flax, and sunflower. Most hemp breeding that has been conducted to date has been for fiber characteristics, so that there should be considerable improvement possible. The second breeding goal is for larger seeds, as these are more easily shelled. Third is breeding for specific seed components. Notable are the health-promoting gamma-linolenic acid; improving the amino acid spectrum of the protein; and increasing the antioxidant level, which would not only have health benefits but could increase the shelf life of hemp oil and foods.
We use cookies and similar technologies to improve your browsing experience, personalize content and offers, show targeted ads, analyze traffic, and better understand you. We may share your information with third-party partners for marketing purposes. To learn more and make choices about data use, visit our Advertising Policy and Privacy Policy. By clicking “Accept and Continue” below, (1) you consent to these activities unless and until you withdraw your consent using our rights request form, and (2) you consent to allow your data to be transferred, processed, and stored in the United States.
In the United States, non-FDA approved CBD products are classified as Schedule I drugs under the Controlled Substances Act.[63] This means that production, distribution, and possession of non-FDA approved CBD products is illegal under federal law. In addition, in 2016 the Drug Enforcement Administration added "marijuana extracts" to the list of Schedule I drugs, which it defined as "an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant."[64] Previously, CBD had simply been considered "marijuana", which is a Schedule I drug.[63][65]
All this means that scientists can still only obtain marijuana-derived CBD from farms licensed by the National Institute on Drug Abuse (which until this year meant only one farm owned by the University of Mississippi). As for whether you should have a preference for CBD that comes from hemp, marijuana, or a pure synthetically produced version, there are some theories that THC—and even the smell and taste of cannabis—might make CBD more effective, but Bonn-Miller says these ideas have yet to be proven.
Karl W. Hillig, a graduate student in the laboratory of long-time Cannabis researcher Paul G. Mahlberg[77] at Indiana University, conducted a systematic investigation of genetic, morphological, and chemotaxonomic variation among 157 Cannabis accessions of known geographic origin, including fiber, drug, and feral populations. In 2004, Hillig and Mahlberg published a chemotaxonomic analysis of cannabinoid variation in their Cannabis germplasm collection. They used gas chromatography to determine cannabinoid content and to infer allele frequencies of the gene that controls CBD and THC production within the studied populations, and concluded that the patterns of cannabinoid variation support recognition of C. sativa and C. indica as separate species, but not C. ruderalis.[52] The authors assigned fiber/seed landraces and feral populations from Europe, Central Asia, and Turkey to C. sativa. Narrow-leaflet and wide-leaflet drug accessions, southern and eastern Asian hemp accessions, and feral Himalayan populations were assigned to C. indica. In 2005, Hillig published a genetic analysis of the same set of accessions (this paper was the first in the series, but was delayed in publication), and proposed a three-species classification, recognizing C. sativa, C. indica, and (tentatively) C. ruderalis.[55] In his doctoral dissertation published the same year, Hillig stated that principal components analysis of phenotypic (morphological) traits failed to differentiate the putative species, but that canonical variates analysis resulted in a high degree of discrimination of the putative species and infraspecific taxa.[78] Another paper in the series on chemotaxonomic variation in the terpenoid content of the essential oil of Cannabis revealed that several wide-leaflet drug strains in the collection had relatively high levels of certain sesquiterpene alcohols, including guaiol and isomers of eudesmol, that set them apart from the other putative taxa.[79] Hillig concluded that the patterns of genetic, morphological, and chemotaxonomic variation support recognition of C. sativa and C. indica as separate species. He also concluded there is little support to treat C. ruderalis as a separate species from C. sativa at this time, but more research on wild and weedy populations is needed because they were underrepresented in their collection.
Jump up ^ Hayakawa K, Mishima K, Nozako M, Ogata A, Hazekawa M, Liu AX, Fujioka M, Abe K, Hasebe N, Egashira N, Iwasaki K, Fujiwara M (March 2007). "Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance". Neuropharmacology. 52 (4): 1079–87. doi:10.1016/j.neuropharm.2006.11.005. PMID 17320118.

This law provides a framework for commercial industrial hemp production in Montana following approval by the federal government. Provisions added to the 2014 Farm Bill (Section 7606) defined industrial hemp under federal law and recognized state agricultural departments' authority to develop research pilot programs to study the growth, cultivation, and/or marketing of industrial hemp.


One claim is that Hearst believed[dubious – discuss] that his extensive timber holdings were threatened by the invention of the decorticator which he feared would allow hemp to become a cheap substitute for the paper pulp used for newspaper.[121][124] Historical research indicates this fear was unfounded because improvements of the decorticators in the 1930s – machines that separated the fibers from the hemp stem – could not make hemp fiber a cheaper substitute for fibers from other sources. Further, decorticators did not perform satisfactorily in commercial production.[125][121]
This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

The vegetable oils have been classified by “iodine value” as drying (120–200), semi-drying (100–120), and non-drying (80–100), which is determined by the degree of saturation of the fatty acids present (Raie et al. 1995). Good coating materials prepared from vegetable oil depend on the nature and number of double bonds present in the fatty acids. Linseed oil, a drying oil, has a very high percentage of linolenic acid. Hempseed oil has been classified as a semi-drying oil, like soybean oil, and is therefore more suited to edible than industrial oil purposes. Nevertheless hemp oil has found applications in the past in paints, varnishes, sealants, lubricants for machinery, and printing inks. However, such industrial end uses are not presently feasible as the oil is considered too expensive (de Guzman 2001). Larger production volumes and lower prices may be possible, in which case hemp oil may find industrial uses similar to those of linseed (flax), soybean, and sunflower oils, which are presently used in paints, inks, solvents, binders, and in polymer plastics. Hemp shows a remarkable range of variation in oil constituents, and selection for oilseed cultivars with high content of valued industrial constituents is in progress.


Without arguing the merits of the above contentions, we point out that the legitimate use of hemp for non-intoxicant purposes has been inhibited by the continuing ferocious war against drug abuse. In this atmosphere, objective analysis has often been lacking. Unfortunately both proponents and opponents have tended to engage in exaggeration. Increasingly, however, the world is testing the potential of hemp in the field and marketplace, which surely must be the ultimate arbiters. De Guzman (2001), noting the pessimistic USDA report, observed that “Nevertheless, others point to the potential of [the] market. Hemp products have a growing niche market of their own, and the market will remain healthy and be well supported with many competing brands.”

"The data supporting efficacy and dosing are specific to one product: Epidiolex," Bonn-Miller says. "That's not necessarily translatable to 'Joe Bob's CBD Blend.'" A CBD extract you buy online or in a dispensary will almost certainly have less CBD in it, he explains, and will contain other cannabinoids—meaning that it will work differently and will need to be dosed differently. "This is not to say that 'Joe Bob's CBD Blend' definitely isn't going to be effective for pediatric epilepsy, but it means that we need to study it before we know."
Did you get an answer for this? I have the exact same scenario. I'm treating my TN with Tegretol, and recently tried CBD. I think I took too much and there are some weird drug interactions with Tegretol and I felt quite stoned....was alone and talking to myself in my head thinking I was Einstein. It freaked me out a bit but I think I took too much. I'm trying lower doses again as recently my TN seems to be resisting the meds, although I have had a lot of emotional stress, which seems to be a trigger. Thanks!! Anna
Of the 20 known amino acids, hemp supplies them all, including the essential ones the body can’t produce, known as EAAs. About 65 percent of the protein in hemp seeds is edestin, a globulin protein that aids in digestion, similar to the globulin found in human blood plasma, and hemp seeds are the only place they’re found. The other third is made up of the protein albumin.
The U.S. hemp-derived CBD market alone is projected to reach $450 million by 2020, and China's cannabis market could grow to 100 billion yuan by 2022 (approximately $14.5 billion). Hemp is already interwoven into the futures of the automotive, construction, energy, environmental mediation and technology industries. Once fully utilized and legal, this plant could impact the global economic positionings of North America, China and Africa.
In the United States, the CBD drug Epidiolex has been approved by the Food and Drug Administration for treatment of two epilepsy disorders.[13] The U.S. Drug Enforcement Administration has assigned Epidiolex a Schedule V classification while non-Epidiolex CBD remains a Schedule I drug prohibited for any use.[14] CBD is not scheduled under any United Nations drug control treaties, and in 2018 the World Health Organization recommended that it remain unscheduled.[15]
Jump up ^ Vanyukov MM, Tarter RE, Kirillova GP, Kirisci L, Reynolds MD, Kreek MJ, Conway KP, Maher BS, Iacono WG, Bierut L, Neale MC, Clark DB, Ridenour TA (June 2012). "Common liability to addiction and "gateway hypothesis": theoretical, empirical and evolutionary perspective". Drug and Alcohol Dependence (Review). 123 Suppl 1: S3–17. doi:10.1016/j.drugalcdep.2011.12.018. PMC 3600369. PMID 22261179.
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & Guimarães, F. S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Abstract]. Current Pharmaceutical Design, 18(32), 5,131–5,140. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22716160
My dad has severe advanced stage Dementia. Will CBD oil help him at this point? He is now refusing to eat any solid food, but will accept most drinks.In addition, he has lost a great deal of weight even though they're giving him Mega Shakes containing a full meals worth of proteins, etc. He gets at least 4 of these a day..some which he refuses. Is his Dementia too far gone for CBD oils to help him?
Side effects of CBD include sleepiness, decreased appetite, diarrhea, fatigue, malaise, weakness, sleeping problems, and others.[3] It does not have intoxicating effects like those caused by THC, and may have an opposing effect on disordered thinking and anxiety produced by THC.[7][10][11] CBD has been found to interact with a variety of different biological targets, including cannabinoid receptors and other neurotransmitter receptors.[7][12] The mechanism of action of CBD in terms of its psychoactive and therapeutic effects is not fully clear.[7]

Another concern is about medications with which CBD might interact. This won’t be an issue with most drugs, says Sunil Kumar Aggarwal, M.D., Ph.D., a palliative medicine physician and scientist who studies cannabis and integrates it into his Seattle medical practice. The exceptions are blood thinners, IV antibiotics, and other drugs whose exact dosing is crucial and must be monitored closely, he says. (Of course, if you have a health problem, talk to your doctor before using CBD, and never take it instead of seeing your physician for a serious condition.)
Former House Speaker John Boehner (R-OH) is the latest public official to endorse significant marijuana law reforms after leaving office. “Over the last 10 or 15 years, the American people’s attitudes have changed dramatically,” he told Bloomberg. “I find myself in that same position.” Boehner, along with former Massachusetts Gov. Bill Weld (R), is joining … Continue reading Former GOP House Speaker Backs Marijuana Descheduling, Joins Cannabiz
After seasonal harvests of specific cultivars, these high-CBD hemp crops are put through a specialized solvent-free extraction process to yield a hemp oil that is naturally high in cannabidiol. This pure hemp extract is then tested for safety, quality, and cannabinoid content before being exported to our processing facilities in the United States. Importing any cannabis or hemp product into the United States is a complicated and serious task, so we leave nothing to chance before our high-CBD hemp oil makes its journey across the Atlantic Ocean.
Hemp’s greatest obstacle is its association with psychoactive cannabis, despite the important distinction that hemp contains only nominal amounts (no more than 0.3%) of the psychoactive ingredient, tetrahydrocannabinol (THC). Although the U.S. is the largest importer of hemp products according to the Hemp Business Journal (a New Frontier Data subsidiary), hemp itself has struggled to gain social acceptance in the country and elsewhere. For instance, current U.S. legislation only permits universities and states performing agricultural or academic research to cultivate hemp. However, the 2018 Farm Bill currently in Congress would grant hemp full legalization across the nation. Passage of this bill would be a key step in promoting public acceptance in the U.S. and elsewhere, allowing the country to participate in the rapidly growing global hemp market.
An industrial hemp license issued by the state provides authorization for the production of industrial hemp at a particular growing area by a particular individual or entity. Licenses will expire on the last day of December of the year that they are issued. Renewals do not require new fingerprinting unless the department requests it or if the corporate officers have changed.
"Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia.
Hi, I had ovarian cancer stage 2 and went to do chemotherapy for 16 times in 2014. It came back last year 2016 but I did not do chemotherapy or radiation therapy as suggested by the doctor. I am taking hormone therapy at the moment. I would like to use cannabis oil but which one and how much CBD and how much THC should I take for ovarian cancer? Can anyone give some idea?. Thank you very much.
CBD does not appear to have any psychotropic ("high") effects such as those caused by ∆9-THC in marijuana, but may have anti-anxiety and anti-psychotic effects.[10] As the legal landscape and understanding about the differences in medical cannabinoids unfolds, it will be increasingly important to distinguish "medical marijuana" (with varying degrees of psychotropic effects and deficits in executive function) – from "medical CBD therapies” which would commonly present as having a reduced or non-psychoactive side effect profile.[10][60]
In December 2013, Uruguay became the first country to legalize growing, sale and use of cannabis.[219] After a long delay in implementing the retail component of the law, in 2017 sixteen pharmacies were authorized to sell cannabis commercially.[220] On June 19, 2018, the Canadian Senate passed a bill and the Prime Minister announced the effective legalization date as October 17, 2018.[37][221] Canada is the second nation to legalize the drug.[222]
A randomized, placebo-controlled, crossover pilot study of nabiximols in 16 patients with chemotherapy-induced neuropathic pain showed no significant difference between the treatment and placebo groups. A responder analysis, however, demonstrated that five patients reported a reduction in their pain of at least 2 points on an 11-point scale, suggesting that a larger follow-up study may be warranted.[55]
Several studies have demonstrated the therapeutic effects of cannabinoids for nausea and vomiting in the advanced stages of illnesses such as cancer and AIDS. Dronabinol (tetrahydrocannabinol) has been available by prescription for more than a decade in the USA. Other therapeutic uses of cannabinoids are being demonstrated by controlled studies, including treatment of asthma and glaucoma, as an antidepressant, appetite stimulant, anticonvulsant and anti-spasmodic, research in this area should continue. For example, more basic research on the central and peripheral mechanisms of the effects of cannabinoids on gastrointestinal function may improve the ability to alleviate nausea and emesis. More research is needed on the basic neuropharmacology of THC and other cannabinoids so that better therapeutic agents can be found.
Some of the research focuses that were explored in 2018 were: comparison of various agronomic factors on industrial hemp (planting dates, tillage regimens, range of soil fertility, etc.); hemp variety comparison for suitability to PA growing conditions; study of the effectiveness of potential herbicide products; comparison of hemp’s capability for weed suppression to other crops; surveying hemp crops for presence of arthropod and disease pests; evaluation of hemp’s performance for phytoremediation and land reclamation; study of hemp seed oil processing and marketability; development of industrial hemp products (using grain, stalks and flowers); genetic selection for desired hemp variety characteristics; and evaluations of hemp as an animal feed ingredient (cattle).  
Thank you for sharing your story. It is amazing the stories I have heard and the things you here the politicians debating over. The truth is out. They need to get over there guilty pride and pharmaceutical needs to be slapped down a few pegs. This is happening we just need to defend the corporations that back the oil, the pharma, any other corporation that doesn’t fight a health and balance model.

Karl W. Hillig, a graduate student in the laboratory of long-time Cannabis researcher Paul G. Mahlberg[77] at Indiana University, conducted a systematic investigation of genetic, morphological, and chemotaxonomic variation among 157 Cannabis accessions of known geographic origin, including fiber, drug, and feral populations. In 2004, Hillig and Mahlberg published a chemotaxonomic analysis of cannabinoid variation in their Cannabis germplasm collection. They used gas chromatography to determine cannabinoid content and to infer allele frequencies of the gene that controls CBD and THC production within the studied populations, and concluded that the patterns of cannabinoid variation support recognition of C. sativa and C. indica as separate species, but not C. ruderalis.[52] The authors assigned fiber/seed landraces and feral populations from Europe, Central Asia, and Turkey to C. sativa. Narrow-leaflet and wide-leaflet drug accessions, southern and eastern Asian hemp accessions, and feral Himalayan populations were assigned to C. indica. In 2005, Hillig published a genetic analysis of the same set of accessions (this paper was the first in the series, but was delayed in publication), and proposed a three-species classification, recognizing C. sativa, C. indica, and (tentatively) C. ruderalis.[55] In his doctoral dissertation published the same year, Hillig stated that principal components analysis of phenotypic (morphological) traits failed to differentiate the putative species, but that canonical variates analysis resulted in a high degree of discrimination of the putative species and infraspecific taxa.[78] Another paper in the series on chemotaxonomic variation in the terpenoid content of the essential oil of Cannabis revealed that several wide-leaflet drug strains in the collection had relatively high levels of certain sesquiterpene alcohols, including guaiol and isomers of eudesmol, that set them apart from the other putative taxa.[79] Hillig concluded that the patterns of genetic, morphological, and chemotaxonomic variation support recognition of C. sativa and C. indica as separate species. He also concluded there is little support to treat C. ruderalis as a separate species from C. sativa at this time, but more research on wild and weedy populations is needed because they were underrepresented in their collection.
Breeding for low THC cultivars in Europe has been reviewed by Bócsa (1998), Bócsa and Karus (1998), and Virovets (1996). Some researchers have claimed to have produced essentially THC-free strains, although at present no commercial cultivar seems to be 100% free of THC. THC content has proven to be more easily reduced in monoecious than in dioecious varieties. It should be possible to select THC-free strains, and there has been speculation that genetic engineering could be helpful in this regard. As a strategic economic and political tactic, France has been attempting for several years to have the European Union (EU) adopt legislation forbidding the cultivation of industrial hemp cultivars with more than 0.1% THC, which would mean that primarily French varieties would have to be cultivated in Europe. However, the Canadian government has found that some French material has proven to be excessively high in THC.
We also rated the product based on the type of CBD they used: isolate, full-spectrum decarb, broad-spectrum, or distillate. There’s a lot of debate around what is actually best, but our first decision was to give points to CBD oil that contains a range of cannabinoids. While there are certainly people with good reasons for choosing an isolate, there’s a lot of good evidence that CBD works better in combination with other cannabinoids (this is called the “entourage effect”).

Hemp is not the same as marijuana. One really has nothing to do with the other. Hemp was made illegal back in the days when cotton was king in the south and southern cotton plantation owners did not want the competition. They lobbied for, and got a law against hemp being grown nationwide. It never had to do with drugs at that time, and still doesn’t. As always, money and government go hand in hand. Now, recently, South Carolina has legalized growing hemp again, which is the only state in 50 to do so. We will hope for more enlightened agri-business legislation across the nation, soon.
I have idiopathic peripheral neuropathy ... the only thing they found that would work is lyrica. I picked up some CBD oil yesterday morning. I am prescribed to take 75 mg of lyrica 3x per day. I took one yesterday morning and have only used the CBD oil since. I bought the Koi brand, flavored, 250 MG. I used a full dropper yesterday late morning and a full dropper yesterday late afternoon. I used it once today (one full dropper) and I am amazingly pain free.
Cannabis, especially the cannabinoid CBD, has also demonstrated its abilities as a powerful anti-convulsant. This property is what accounts for cannabis’ ability to reduce the severity and frequency of seizures, especially for people with epilepsy. In the United States, epilepsy is the most widely adopted qualifying condition for medical cannabis use, especially for children.
Hi, I have had spondylolisthesis since age 11 which left me with extreme nerve pain...restless leg syndrome. Had 3 spinal ops and also had hip surgery 2 years ago. have asthma and hypothyroidism. I can deal with everything else but this nerve pain is insane. Used Gabapentin for 9 years and now its not in the market in Nairobi, Kenya where I live. Am on Lyrica, which is not working. I started Cbd oil in August but now found my body has become immune to the effects of pain releif I was getting. Can anyone suggest what strength oil/cbd supplement I should aim for? Currently am making flapjacks with weed, have one every night but this makes me high which I dont want. I still wake up in pain at night, please help.
The pulp and paper industry based on wood has considered the use of hemp for pulp, but only on an experimental basis. Hemp’s long fibers could make paper more recyclable. Since virgin pulp is required for added strength in the recycling of paper, hemp pulp would allow for at least twice as many cycles as wood pulp. However, various analyses have concluded that the use of hemp for conventional paper pulp is not profitable (Fertig 1996).
Hemp oil has never been as popular as other marijuana products. With little to no THC, CBD-rich strains of cannabis don’t deliver the pleasant buzz recreational users seek out in marijuana. In the 1970s, however, scientists found that cannabidiol was effective in reducing seizures. The brain’s endocannabinoid system contains receptors that respond to CBD, producing anticonvulsant effects. Being plant-derived and native to the brain’s own chemistry, CBD is therefore one of the most natural options for seizure treatment available today. Still, not many people took interest in CBD until 2013, when a CNN documentary special, Weed, hosted by the network’s chief medical correspondent, Dr. Sanjay Gupta, highlighted CBD’s effectiveness in combating seizures. Since then, demand for hemp oil products has exploded.
Use of industrial hemp plant and its cultivation was commonplace until the 1900s, when it was associated with its genetic sibling aka Drug-Type Cannabis species (which contain higher levels of psychoactive THC). Influential groups misconstrued hemp as a dangerous 'drug', even though it is not a 'drug' and it has the potential to be a sustainable & profitable alternative crop.
×